Biology and clinical relevance of EpCAM DOI Creative Commons
Laura Keller, Stefan Werner, Klaus Pantel

et al.

Cell Stress, Journal Year: 2019, Volume and Issue: 3(6), P. 165 - 180

Published: June 5, 2019

Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein primarily known to mediate homotypic contacts in epithelia tissues. Because EpCAM expression limited normal and malignant epithelia, it has been used as diagnostic marker for the detection of carcinoma cells mesenchymal organs such blood, bone marrow or lymph nodes. In particular, molecular characterization EpCAM-positive circulating tumor (CTCs) blood patients gained considerable interest over past ten years. considered an molecule, but recent studies have shown diverse biological functions including regulation proliferation cancer stemness. this review, we summarize current knowledge on properties with emphasis mechanisms involved progression discuss clinical implications these findings use marker.

Language: Английский

Detection and localization of surgically resectable cancers with a multi-analyte blood test DOI Open Access
Joshua D. Cohen, Lu Li, Yuxuan Wang

et al.

Science, Journal Year: 2018, Volume and Issue: 359(6378), P. 926 - 930

Published: Jan. 18, 2018

Earlier detection is key to reducing cancer deaths. Here, we describe a blood test that can detect eight common types through assessment of the levels circulating proteins and mutations in cell-free DNA. We applied this test, called CancerSEEK, 1005 patients with nonmetastatic, clinically detected cancers ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests were positive median 70% types. The sensitivities ranged from 69 98% for five (ovary, esophagus) which there are no screening available average-risk individuals. specificity was greater than 99%: only 7 812 healthy controls scored positive. In addition, localized small number anatomic sites 83% patients.

Language: Английский

Citations

2323
Current and future perspectives of liquid biopsies in genomics-driven oncology DOI
Ellen Heitzer, Imran S. Haque,

Charles E. S. Roberts

et al.

Nature Reviews Genetics, Journal Year: 2018, Volume and Issue: 20(2), P. 71 - 88

Published: Nov. 8, 2018

Language: Английский

Citations

1173
Liquid biopsy and minimal residual disease — latest advances and implications for cure DOI
Klaus Pantel, Catherine Alix‐Panabières

Nature Reviews Clinical Oncology, Journal Year: 2019, Volume and Issue: 16(7), P. 409 - 424

Published: Feb. 22, 2019

Language: Английский

Citations

865
Liquid biopsy: current technology and clinical applications DOI Creative Commons
Mina Nikanjam, Shumei Kato, Razelle Kurzrock

et al.

Journal of Hematology & Oncology, Journal Year: 2022, Volume and Issue: 15(1)

Published: Sept. 12, 2022

Abstract Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA), circulating tumor DNA (ctDNA), and cells (CTCs) can be isolated from the blood other body fluids. This review will focus on current technologies clinical applications liquid biopsies. ctDNA/cfDNA has been analyzed using many techniques, e.g., droplet digital polymerase chain reaction, beads, emulsion, amplification, magnetics (BEAMing), tagged-amplicon deep sequencing (TAm-Seq), personalized by (CAPP-Seq), whole genome bisulfite (WGBS-Seq), exome (WES), (WGS). CTCs have biomarker-based cell capture, positive or negative enrichment based biophysical properties. being exploited in variety of applications: differentiating unique immune checkpoint blockade response patterns serial samples; predicting baseline biopsy characteristics; resistance to targeted therapy chemotherapy as well immunotherapy, including CAR-T cells, sampling; assessing shed multiple metastatic sites; potentially actionable alterations; analyzing prognosis burden, after surgery; interrogating difficult-to tumors; detecting at early stages. The latter limited small amounts tumor-derived components into circulation; furthermore, cfDNA assessment all cancers confounded clonal hematopoeisis indeterminate potential, especially elderly. technically more difficult isolate cfDNA, but permit functional assays, evaluation CTC-derived DNA, RNA proteins, single-cell analysis. Blood less invasive than tissue hence amenable collection, which provide critical information real time. In conclusion, is powerful tool, remarkable advances this technology impacted aspects oncology, diagnosis management refractory disease. Future research may fluids beyond blood, such ascites, effusions, urine, cerebrospinal fluid, methylation elements exosomes.

Language: Английский

Citations

493
The lingering mysteries of metastatic recurrence in breast cancer DOI Creative Commons
Alessandra I. Riggio, Katherine E. Varley, Alana L. Welm

et al.

British Journal of Cancer, Journal Year: 2020, Volume and Issue: 124(1), P. 13 - 26

Published: Nov. 26, 2020

Despite being the hallmark of cancer that is responsible for highest number deaths, very little known about biology metastasis. Metastatic disease typically manifests after a protracted period undetectable following surgery or systemic therapy, owing to relapse recurrence. In case breast cancer, metastatic can occur months decades initial diagnosis and treatment. this review, we provide an overview key factors influence recurrence, with goal highlighting critical unanswered questions still need be addressed make difference in mortality patients.

Language: Английский

Citations

452
Clinical utility of circulating non-coding RNAs — an update DOI
Simone Anfossi, Anna Babayan, Klaus Pantel

et al.

Nature Reviews Clinical Oncology, Journal Year: 2018, Volume and Issue: 15(9), P. 541 - 563

Published: May 21, 2018

Language: Английский

Citations

413
Clinical implications of intratumor heterogeneity: challenges and opportunities DOI Creative Commons
Santiago Ramón y Cajal, Marta Sesé,

Claudia Capdevila

et al.

Journal of Molecular Medicine, Journal Year: 2020, Volume and Issue: 98(2), P. 161 - 177

Published: Jan. 22, 2020

Abstract In this review, we highlight the role of intratumoral heterogeneity, focusing on clinical and biological ramifications phenomenon poses. Intratumoral heterogeneity arises through complex genetic, epigenetic, protein modifications that drive phenotypic selection in response to environmental pressures. Functionally, provides tumors with significant adaptability. This ranges from mutual beneficial cooperation between cells, which nurture features such as growth metastasis, narrow escape survival clonal cell populations have adapted thrive under specific conditions hypoxia or chemotherapy. These dynamic intercellular interplays are guided by a Darwinian landscape tumor microenvironment. Understanding involved drivers functional consequences is challenging but also promises provide novel insight needed confront problem therapeutic resistance tumors.

Language: Английский

Citations

389
Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology DOI Creative Commons
Raffaele Palmirotta, Domenica Lovero, Paola Cafforio

et al.

Therapeutic Advances in Medical Oncology, Journal Year: 2018, Volume and Issue: 10

Published: Jan. 1, 2018

Over the last decades, concept of precision medicine has dramatically renewed field medical oncology; introduction patient-tailored therapies significantly improved all measurable outcomes. Liquid biopsy is a revolutionary technique that opening previously unexpected perspectives. It consists detection and isolation circulating tumor cells, DNA exosomes, as source genomic proteomic information in patients with cancer. Many technical hurdles have been resolved thanks to newly developed techniques next-generation sequencing analyses, allowing broad application liquid wide range settings. Initially correlated prognosis, data are now being studied for cancer diagnosis, hopefully including screenings, most importantly prediction response or resistance given treatments. In particular, identification specific mutations target genes can aid therapeutic decisions, both appropriateness treatment advanced secondary resistance, aiming early diagnose disease progression. Still far from reality but ongoing research leading way new era oncology. This review summarizes main applications

Language: Английский

Citations

379
Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management DOI Creative Commons
Maha Elazezy, Simon A. Joosse

Computational and Structural Biotechnology Journal, Journal Year: 2018, Volume and Issue: 16, P. 370 - 378

Published: Jan. 1, 2018

Precision medicine in the clinical management of cancer may be achieved through diagnostic platform called "liquid biopsy". This method utilizes detection biomarkers blood for prognostic and predictive purposes. One latest born markers under investigation field liquid biopsy patients is circulating tumor DNA (ctDNA). ctDNA released by cells different mechanisms can therefore provide information about genomic make-up currently present patient. Through longitudinal ctDNA-based biopsies, dynamics monitored to predict assess drug response and/or resistance. However, because highly fragmented its concentration extremely low a high background normal DNA, screening relevant mutations challenging. Although significant progress has been made advancing analysis last few years, current challenges include standardization increasing techniques single molecule sensitivity combination with perfect specificity. review focuses on potential role patients, technologies that are being employed, hurdles still need taken achieve towards precision medicine.

Language: Английский

Citations

309
Liquid Biopsy: General Concepts DOI
Geoffroy Poulet,

Joséphine Massias,

Valérie Taly

et al.

Acta Cytologica, Journal Year: 2019, Volume and Issue: 63(6), P. 449 - 455

Published: Jan. 1, 2019

Liquid biopsy provides the opportunity of detecting, analyzing and monitoring cancer in various body effluents such as blood or urine instead a fragment tissue. It is composed different biological matrices circulating tumor cells (CTCs), cell free nucleic acids, exosomes tumors “educated platelets.” In addition to representing non- minimally invasive procedure, it should represent better view heterogeneity allows for real-time evolution. Recent technological molecular advances, greatly facilitated by use microfluidics many cases, have permitted large progresses both our ability purify analyze liquid components. particular, great developments droplet-based digital PCR optimizations next generation sequencing technologies are central several validations CTC-free DNA strong biomarker. However, complete adoption clinics will require pursuing recent efforts standardization procedures on pre-analytical analytical aspects.

Language: Английский

Citations

292